ELVAF
Price
$0.90
Change
-$0.05 (-5.26%)
Updated
Nov 8 closing price
Capitalization
9.68M
REPL
Price
$10.02
Change
+$0.38 (+3.94%)
Updated
May 2, 04:59 PM (EDT)
Capitalization
742.42M
13 days until earnings call
Ad is loading...

ELVAF vs REPL

Header iconELVAF vs REPL Comparison
Open Charts ELVAF vs REPLBanner chart's image
Evolva Holding AG
Price$0.90
Change-$0.05 (-5.26%)
Volume$194
Capitalization9.68M
Replimune Group
Price$10.02
Change+$0.38 (+3.94%)
Volume$11.22K
Capitalization742.42M
ELVAF vs REPL Comparison Chart
Loading...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ELVAF vs. REPL commentary
May 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELVAF is a Hold and REPL is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
May 03, 2025
Stock price -- (ELVAF: $0.90 vs. REPL: $9.64)
Brand notoriety: ELVAF and REPL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ELVAF: 100% vs. REPL: 82%
Market capitalization -- ELVAF: $9.68M vs. REPL: $742.42M
ELVAF [@Biotechnology] is valued at $9.68M. REPL’s [@Biotechnology] market capitalization is $742.42M. The market cap for tickers in the [@Biotechnology] industry ranges from $293.01B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELVAF’s FA Score shows that 1 FA rating(s) are green whileREPL’s FA Score has 1 green FA rating(s).

  • ELVAF’s FA Score: 1 green, 4 red.
  • REPL’s FA Score: 1 green, 4 red.
According to our system of comparison, both ELVAF and REPL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

REPL’s TA Score shows that 5 TA indicator(s) are bullish.

  • REPL’s TA Score: 5 bullish, 4 bearish.

Price Growth

ELVAF (@Biotechnology) experienced а 0.00% price change this week, while REPL (@Biotechnology) price change was +6.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.36%. For the same industry, the average monthly price growth was +8.08%, and the average quarterly price growth was -5.89%.

Reported Earning Dates

REPL is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REPL($742M) has a higher market cap than ELVAF($9.68M). ELVAF YTD gains are higher at: 0.000 vs. REPL (-20.396). ELVAF has higher annual earnings (EBITDA): 1.05M vs. REPL (-216.51M). REPL has more cash in the bank: 537M vs. ELVAF (6.75M). ELVAF (0) and REPL (0) have equivalent revenues.
ELVAFREPLELVAF / REPL
Capitalization9.68M742M1%
EBITDA1.05M-216.51M-0%
Gain YTD0.000-20.396-
P/E RatioN/AN/A-
Revenue00-
Total Cash6.75M537M1%
Total DebtN/A76M-
FUNDAMENTALS RATINGS
ELVAF vs REPL: Fundamental Ratings
ELVAF
REPL
OUTLOOK RATING
1..100
4126
VALUATION
overvalued / fair valued / undervalued
1..100
19
Undervalued
28
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
5195
PRICE GROWTH RATING
1..100
7157
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ELVAF's Valuation (19) in the null industry is in the same range as REPL (28) in the Biotechnology industry. This means that ELVAF’s stock grew similarly to REPL’s over the last 12 months.

ELVAF's Profit vs Risk Rating (100) in the null industry is in the same range as REPL (100) in the Biotechnology industry. This means that ELVAF’s stock grew similarly to REPL’s over the last 12 months.

ELVAF's SMR Rating (51) in the null industry is somewhat better than the same rating for REPL (95) in the Biotechnology industry. This means that ELVAF’s stock grew somewhat faster than REPL’s over the last 12 months.

REPL's Price Growth Rating (57) in the Biotechnology industry is in the same range as ELVAF (71) in the null industry. This means that REPL’s stock grew similarly to ELVAF’s over the last 12 months.

REPL's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ELVAF (100) in the null industry. This means that REPL’s stock grew similarly to ELVAF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
REPL
RSI
ODDS (%)
Bullish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 3 days ago
77%
Declines
ODDS (%)
Bearish Trend 29 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
64%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FWMIX61.010.17
+0.28%
American Funds Washington Mutual F3
COSZX12.26N/A
N/A
Columbia Overseas Value Inst
SSRRX5.83N/A
N/A
Touchstone Small Company R6
RMBHX32.47N/A
N/A
RMB A
FEFRX26.74-0.11
-0.41%
First Eagle Rising Dividend Fund R6

ELVAF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELVAF has been loosely correlated with REPL. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if ELVAF jumps, then REPL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELVAF
1D Price
Change %
ELVAF100%
N/A
REPL - ELVAF
60%
Loosely correlated
-1.43%
CLYYF - ELVAF
47%
Loosely correlated
N/A
IBIO - ELVAF
39%
Loosely correlated
-2.83%
GLABF - ELVAF
34%
Loosely correlated
N/A
NRSN - ELVAF
24%
Poorly correlated
+5.90%
More

REPL and

Correlation & Price change

A.I.dvisor indicates that over the last year, REPL has been loosely correlated with ELVAF. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if REPL jumps, then ELVAF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REPL
1D Price
Change %
REPL100%
-1.43%
ELVAF - REPL
60%
Loosely correlated
N/A
RCKT - REPL
44%
Loosely correlated
+3.01%
AXON - REPL
41%
Loosely correlated
+1.27%
ORMP - REPL
39%
Loosely correlated
-2.16%
KYMR - REPL
39%
Loosely correlated
+0.82%
More